Cooperative dissolution of peptidomimetic vesicles and amyloid β fibrils
The aggregation of amyloid proteins in the brain is a significant neurotoxic event that
contributes to neurodegenerative disorders. The aggregation of amyloid beta (Aβ) …
contributes to neurodegenerative disorders. The aggregation of amyloid beta (Aβ) …
Modulation of the Aβ peptide aggregation pathway by KP1019 limits Aβ-associated neurotoxicity
Alzheimer's disease (AD) is a neurodegenerative disorder that is increasing worldwide due
to increased life expectancy. AD is characterized by two pathological hallmarks in the brain …
to increased life expectancy. AD is characterized by two pathological hallmarks in the brain …
Aza-Residue Modulation of Cyclic d,l-α-Peptide Nanotube Assembly with Enhanced Anti-Amyloidogenic Activity
M Habashi, PS Chauhan, S Vutla… - Journal of medicinal …, 2023 - ACS Publications
Transient soluble oligomers of amyloid-β (Aβ) are considered among the most toxic species
in Alzheimer's disease (AD). Soluble Aβ oligomers accumulate early prior to insoluble …
in Alzheimer's disease (AD). Soluble Aβ oligomers accumulate early prior to insoluble …
[引用][C] Designed short peptides that form amyloid‐like fibrils in coassembly with amyloid β‐peptide (Aβ) decrease the toxicity of Aβ to neuronal PC12 cells
M Suzuki, T Takahashi, J Sato, M Mie… - …, 2010 - Wiley Online Library
Protein misfolding and aggregation are closely associated with neurodegenerative
diseases.[1–4] The aggregation of amyloid βpeptide (Aβ) and tau protein is thought to cause …
diseases.[1–4] The aggregation of amyloid βpeptide (Aβ) and tau protein is thought to cause …
Multivalent Polymer–Peptide Conjugates: A General Platform for Inhibiting Amyloid Beta Peptide Aggregation
Protein aggregation is implicated in multiple deposition diseases including Alzheimer's
Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides …
Disease, which features the formation of toxic aggregates of amyloid beta (Aβ) peptides …
Hydrophobic C-Terminal Peptide Analog Aβ31–41 Protects the Neurons from Aβ-Induced Toxicity
R Mallesh, J Khan, PK Gharai, MU Arshi… - ACS Chemical …, 2024 - ACS Publications
Spontaneous aggregation of amyloid beta (Aβ) leads to the formation of neurotoxic senile
plaque considered as the most crucial event in Alzheimer's disease (AD) progression …
plaque considered as the most crucial event in Alzheimer's disease (AD) progression …
A chemical perspective to the anti-amyloid action of compounds and a nanoparticle based assay for screening amyloid inhibitors
N Gour, B Koshti, VS Kshtriya - 2019 - chemrxiv.org
Aggregation of amyloid beeta 1-42 (Aβ42) peptide causes the formation of clustered
deposits knows as amyloid plaques in the brain which leads to neuronal dysfunction and …
deposits knows as amyloid plaques in the brain which leads to neuronal dysfunction and …
Assembly of nanoconjugates as new kind inhibitor of the aggregation of amyloid peptides associated with Alzheimer's disease
C Li, J Lu, X Hu, C Feng, Y Xiang… - Particle & Particle …, 2018 - Wiley Online Library
The inhibition of amyloid‐β (Aβ) aggregation has been regarded as the primary therapeutic
strategy for Alzheimer's diseases (AD). Currently, many kinds of amyloid inhibitors have …
strategy for Alzheimer's diseases (AD). Currently, many kinds of amyloid inhibitors have …
A peptide based pro-drug disrupts Alzheimer's amyloid into non-toxic species and reduces aβ induced toxicity in vitro
Aggregation of Amyloid β (Aβ) in the interneuronal spaces is a major etiopathological factor
for onset and progression of Alzheimer's disease (AD). Since the mechanism of aggregation …
for onset and progression of Alzheimer's disease (AD). Since the mechanism of aggregation …
Amyloid against amyloid: Dimeric amyloid fragment ameliorates cognitive impairments by direct clearance of oligomers and plaques
Amyloid‐β (Aβ) in the form of neurotoxic aggregates is regarded as the main pathological
initiator and key therapeutic target of Alzheimer's disease. However, anti‐Aβ drug …
initiator and key therapeutic target of Alzheimer's disease. However, anti‐Aβ drug …